Key statistics
On Friday, Terns Pharmaceuticals Inc (430:BER) closed at 9.00, -11.76% below its 52-week high of 10.20, set on Sep 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.85 |
---|---|
High | 9.45 |
Low | 8.80 |
Bid | 8.85 |
Offer | 9.65 |
Previous close | 9.05 |
Average volume | 1.19k |
---|---|
Shares outstanding | 84.40m |
Free float | 83.34m |
P/E (TTM) | -- |
Market cap | 845.68m USD |
EPS (TTM) | -1.31 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 19:08 BST.
More ▼
Announcements
- Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Terns Announces Pricing of Upsized $150.15 Million Public Offering
- Terns Announces Proposed Public Offering
- Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
- Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
- Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
- Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
More ▼